NCT03400995View on ClinicalTrials.gov

A Study to Evaluate the Pharmacokinetics, Metabolism, and Excretion of AK0529

PHASE1CompletedINTERVENTIONAL
Enrollment

7

Participants

Timeline

Start Date

January 5, 2018

Primary Completion Date

February 27, 2018

Study Completion Date

August 30, 2018

Conditions
Healthy
Interventions
DRUG

AK0529

A solution containing 300 mg radiolabelled AK0529.

Trial Locations (1)

Unknown

Quotient Clinical, Nottingham

All Listed Sponsors
lead

Shanghai Ark Biopharmaceutical Co., Ltd.

INDUSTRY

NCT03400995 - A Study to Evaluate the Pharmacokinetics, Metabolism, and Excretion of AK0529 | Biotech Hunter | Biotech Hunter